Bhumsuk Keam

17.1k total citations · 3 hit papers
373 papers, 9.9k citations indexed

About

Bhumsuk Keam is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Bhumsuk Keam has authored 373 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 228 papers in Oncology, 158 papers in Pulmonary and Respiratory Medicine and 71 papers in Surgery. Recurrent topics in Bhumsuk Keam's work include Lung Cancer Treatments and Mutations (101 papers), Cancer Immunotherapy and Biomarkers (75 papers) and Lung Cancer Research Studies (54 papers). Bhumsuk Keam is often cited by papers focused on Lung Cancer Treatments and Mutations (101 papers), Cancer Immunotherapy and Biomarkers (75 papers) and Lung Cancer Research Studies (54 papers). Bhumsuk Keam collaborates with scholars based in South Korea, United States and Ethiopia. Bhumsuk Keam's co-authors include Dae Seog Heo, Tae Min Kim, Se‐Hoon Lee, Dong‐Wan Kim, Yoon Kyung Jeon, Doo Hyun Chung, Dong‐Wan Kim, Miso Kim, Chan-Young Ock and Seock‐Ah Im and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Nature Communications.

In The Last Decade

Bhumsuk Keam

351 papers receiving 9.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

2017 607 citations Vivek Subbiah, Robert J. Kreitman et al. Journal of Clinical Oncology profile →
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

2018 329 citations Tanguy Y. Seiwert, Makoto Tahara et al. profile →
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

2022 183 citations Vivek Subbiah, Robert J. Kreitman et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bhumsuk Keam South Korea	50	6.1k	4.0k	2.1k	1.6k	1.4k	373	9.9k
Daniel D. Karp United States	43	4.8k 0.8×	3.8k 1.0×	2.9k 1.4×	1.6k 1.0×	1.0k 0.7×	217	9.4k
Arnoud J. Templeton Switzerland	40	5.6k 0.9×	2.6k 0.7×	1.1k 0.5×	1.9k 1.2×	1.5k 1.1×	152	8.6k
Gilberto de Castro Brazil	36	8.0k 1.3×	5.4k 1.3×	1.5k 0.7×	1.8k 1.1×	943 0.7×	215	10.7k
George Fountzilas Greece	54	7.7k 1.3×	3.7k 0.9×	3.1k 1.5×	2.1k 1.3×	2.3k 1.6×	576	12.8k
George Pentheroudakis Greece	43	4.5k 0.7×	1.5k 0.4×	1.6k 0.7×	1.3k 0.9×	983 0.7×	228	7.6k
Keyue Ding Canada	45	8.1k 1.3×	8.4k 2.1×	3.4k 1.6×	2.6k 1.7×	1.7k 1.2×	218	14.5k
Jin Seok Ahn South Korea	55	8.6k 1.4×	7.8k 1.9×	3.2k 1.5×	3.0k 1.9×	962 0.7×	452	13.5k
Lars Bastholt Denmark	42	4.2k 0.7×	1.7k 0.4×	1.8k 0.8×	660 0.4×	1.3k 1.0×	183	8.3k
Rebecca S. Heist United States	51	6.2k 1.0×	6.1k 1.5×	4.3k 2.0×	2.2k 1.4×	995 0.7×	268	11.6k
Guru Sonpavde United States	53	6.9k 1.1×	5.1k 1.3×	3.3k 1.5×	2.3k 1.5×	6.5k 4.7×	628	15.1k

Countries citing papers authored by Bhumsuk Keam

Since Specialization

Citations

This map shows the geographic impact of Bhumsuk Keam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bhumsuk Keam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bhumsuk Keam more than expected).

Fields of papers citing papers by Bhumsuk Keam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bhumsuk Keam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bhumsuk Keam. The network helps show where Bhumsuk Keam may publish in the future.

Co-authorship network of co-authors of Bhumsuk Keam

This figure shows the co-authorship network connecting the top 25 collaborators of Bhumsuk Keam. A scholar is included among the top collaborators of Bhumsuk Keam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bhumsuk Keam. Bhumsuk Keam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yun, Je‐Yeon, Bhumsuk Keam, Na‐Ri Lee, et al.. (2024). Depression, performance status, and discontinued treatment mediate an association of curability belief with prognosis in advanced cancer patients. Scientific Reports. 14(1). 29098–29098.

Keam, Bhumsuk, et al.. (2024). Twenty-five Years Overall Survival Prognostic Value of the Lymph Node Ratio inDe NovoMetastatic Breast Cancer. Anticancer Research. 44(5). 1995–2002.

Falchook, Gerald S., Patricia LoRusso, Jonathan W. Goldman, et al.. (2024). Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2529–2529. 4 indexed citations

Lee, Yun‐Gyoo, Eun Joo Kang, Bhumsuk Keam, et al.. (2023). Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01). Cancers. 15(2). 471–471.

Capdevila, Jaume, Jolanta Krajewska, Jorge Hernando, et al.. (2023). Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 34(3). 347–359. 6 indexed citations

Fayette, Jérôme, Lisa Licitra, Kevin J. Harrington, et al.. (2023). 854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI). Annals of Oncology. 34. S554–S555. 23 indexed citations

Keam, Bhumsuk, Hyun Ae Jung, T.M. Kim, et al.. (2023). 1338P Cerebrospinal fluid pharmacokinetic study of lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG21-01 LAZARUS trial. Annals of Oncology. 34. S771–S772. 1 indexed citations

Kim, Jung‐Sun, Nam Hee Kim, Sun Young Lee, et al.. (2023). Use of high‐flow nasal cannula oxygen therapy for patients with terminal cancer at the end of life. Cancer Medicine. 12(13). 14612–14622. 4 indexed citations

Heo, Dae Seog, Shin Hye Yoo, Bhumsuk Keam, Sang‐Ho Yoo, & Younsuck Koh. (2022). Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement. The Korean Journal of Hospice and Palliative Care. 25(1). 1–11. 9 indexed citations

10.

Humtsoe, Joseph O., Brandon Leonard, Shizhang Ling, et al.. (2021). Newly Identified Members of FGFR1 Splice Variants Engage in Cross-talk with AXL/AKT Axis in Salivary Adenoid Cystic Carcinoma. Cancer Research. 81(4). 1001–1013. 15 indexed citations

11.

Kim, Yejin, et al.. (2021). Practical Considerations in Providing End-of-Life Care for Dying Patients and Their Family in the Era of COVID-19. The Korean Journal of Hospice and Palliative Care. 24(2). 130–134. 3 indexed citations

12.

Glisson, Bonnie S., Rom S. Leidner, Robert L. Ferris, et al.. (2020). Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 26(20). 5358–5367. 63 indexed citations

13.

Sharma, Padmanee, Joohyuk Sohn, Sang Joon Shin, et al.. (2019). Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. Clinical Cancer Research. 26(1). 61–70. 34 indexed citations

14.

Chung, Eun‐Jae, Woo‐Jin Jeong, Young Ho Jung, et al.. (2018). Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases. Oral Oncology. 89. 84–94. 27 indexed citations

15.

Subbiah, Vivek, Robert J. Kreitman, Zev A. Wainberg, et al.. (2017). Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer. Journal of Clinical Oncology. 36(1). 7–13. 607 indexed citations breakdown →

16.

Ock, Chan-Young, Bhumsuk Keam, Sehui Kim, et al.. (2016). Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. Clinical Cancer Research. 22(9). 2261–2270. 201 indexed citations

17.

Yang, Yaewon, Tae Min Kim, Yong‐Oon Ahn, et al.. (2016). Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. Cancer Immunology Research. 4(3). 215–224. 128 indexed citations

18.

Jang, Ji-Young, Soo Jeong Nam, Bhumsuk Keam, et al.. (2016). Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 15(6). 1387–1396. 25 indexed citations

19.

Kim, Tae Min, Dong‐Wan Kim, Soyeon Kim, et al.. (2015). Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1 -Rearranged Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(10). 2379–2387. 99 indexed citations

20.

Go, Heounjeong, Dong‐Wan Kim, Donghyun Kim, et al.. (2013). Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm. Journal of Thoracic Oncology. 8(11). 1445–1450. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact